SUMMARY
There are no effective treatments for postural instability and falls in Progressive Supranuclear Palsy (PSP). Objective of the study was to test the efficacy of theta burst repetitive transcranial magnetic stimulation (rTMS) on postural instability in PSP. Twenty probable PSP patients underwent a session of sham or cerebellar rTMS in a cross-over design. Before and after stimulation, static balance was evaluated with instrumented (lower back accelerometer, Rehagait®, Hasomed, Germany) 30-seconds-trials in semitandem and tandem positions. In tandem and semitandem tasks, active stimulation was associated with longer time without support falls (both p=0.04). In the same tasks, device-extracted parameters revealed significant improvement in area (p=0.007), velocity (p=0.005) and acceleration and jerkiness of sway (p=0.008) in real versus sham stimulation. Cerebellar rTMS thus showed a significant effect on stability in PSP patients, when assessed with mobile digital technology, in a double-blind design. These results should motivate larger and longer trials using non-invasive brain stimulation for PSP patients.
Competing Interest Statement
Andrea Pilotto served in the advisory board of Z-cube (technology division of Zambon pharmaceuticals); he received honoraria from Z-cube s.r.l., Biomarin, Zambon, Nutricia and Chiesi pharmaceuticals. He received research support from Vitaflo Germany and Zambon Italy. Maria Cristina Rizzetti has no financial conflicts to disclose. Alberto Lombardi has no financial conflicts to disclose. Clint Hansen has no financial conflicts to disclose. Michele Biggi has no financial conflicts to disclose. Giacomo Verzeroli has no financial conflicts to disclose. Antonella Martinelli has no financial conflicts to disclose. Robbin Romijnders has no financial conflicts to disclose. Barbara Borroni has no financial conflicts to disclose. Walter Maetzler receives or received funding from the European Union, the German Federal Ministry of Education of Research, Michael J. Fox Foundation, Robert Bosch Foundation, Neuroalliance, Lundbeck and Janssen. He received speaker honoraria from Abbvie, Bayer, GlaxoSmithKline, Licher MT, Roelke Pharma, UCB and Takeda, and was invited to Advisory Boards of Abbvie, Biogen, Lundbeck and Market Access & Pricing Strategy GmbH. He serves as the co-chair of the MDS Technology Task Force. Alessandro Padovani is consultant and served on the scientific advisory board of GE Healthcare, Eli-Lilly and Actelion Ltd Pharmaceuticals, received speaker honoraria from Nutricia, PIAM, Lansgstone Technology, GE Healthcare, Lilly, UCB Pharma and Chiesi Pharmaceuticals. He is founded by European Union, Grant of Ministry of University (MURST), Cariplo Foundation.
Clinical Trial
NCT04222218
Funding Statement
The study was not funded
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The local ethics committee (Comitato Etico Papa Giovanni XXIII, Bergamo, Italy) approved the study (number of protocol approvatiol 193/16) and all patients signed informed consent. Additionally, the study is recorded as NCT04222218 in clinicaltrial.gov.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data will be available for researchers or readers upon reasonable request
